

Table S1. Association between PPI use and controlled attenuation parameter.						
Characteristic	Model 1		Model 2		Model 3	
	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	P-value
PPI use						
No	0		0		0	
Yes	13.41 (8.66-18.16)	<0.01	6.59 (1.82-11.36)	0.01	5.76 (1.00-10.52)	0.02 <sup>a</sup>
PPI						
None	0		0		0	
Omeprazole	15.25 (9.21-21.29)	<0.01	7.36 (1.36-13.37)	0.02	6.93 (0.94-12.93)	0.02 <sup>a</sup>
Pantoprazole	10.07 (1.10-19.03)	0.03	4.88 (-3.92-13.67)	0.28	3.66 (-5.12-12.43)	0.41
Esomeprazole	3.29 (-11.52-18.10)	0.66	-1.82 (-16.27-12.63)	0.81	-3.39 (-17.81-11.02)	0.65
Other	27.63 (7.60-47.66)	0.01	22.09 (2.55-41.63)	0.03	19.90 (0.42-39.37)	<0.05 <sup>a</sup>
Length of PPI use, years						
Not applicable	0		0		0	
<0.5	1.06 (-11.76-13.88)	0.87	-2.64 (-15.15-9.86)	0.68	-2.62 (-15.09-9.84)	0.68
0.5-2.0	7.75 (-3.88-19.38)	0.19	3.86 (-7.49-15.21)	0.51	3.35 (-7.97-14.68)	0.56
>2.0	17.00 (11.47-22.53)	<0.01	9.12 (3.56-14.67)	<0.01	8.08 (2.55-13.62)	<0.01 <sup>a</sup>
Sex						
Male	15.13 (7.96-22.31)	<0.01	8.33 (1.13-15.52)	0.02	7.43 (0.26-14.59)	0.04 <sup>a</sup>
Female	13.44 (7.21-19.68)	<0.01	4.34 (-1.99-10.66)	0.18	3.19 (-3.12-9.51)	0.32
Age, years						
20-39	22.78 (5.12-40.45)	0.01	23.36 (6.07-40.65)	<0.01	22.48 (5.20-39.76)	0.01 <sup>a</sup>
40-59	14.23 (5.2-23.20)	0.01	14.8 (5.97-23.79)	<0.01	13.76 (4.90-22.63)	<0.01 <sup>a</sup>
$\geq 60$	2.98 (-2.92-8.88)	0.32	2.46 (-3.38--8.29)	0.41	2.04 (-3.81-7.89)	0.50
Race/ethnicity						
Non-Hispanic White	17.19 (10.11-24.28)	<0.01	12.60 (5.49-19.72)	<0.01	11.10 (4.00-18.19)	<0.01 <sup>a</sup>
Hispanic	8.86 (-1.90-19.63)	0.11	0.71 (-10.18-11.60)	0.90	0.30 (-10.59-11.19)	0.96

Non-Hispanic Black	8.98 (-0.79-18.76)	0.07	1.65 (-8.24-11.55)	0.74	0.67 (-9.25-10.60)	0.89
Non-Hispanic Asian	11.18(-5.83-28.18)	0.20	6.62(-10.07-23.30)	0.44	6.71 (-9.87-23.29)	0.43
Other	3.26 (-19.72-26.24)	0.78	-7.32 (-30.68-16.04)	0.54	-13.07 (-36.07-9.93)	0.27
BMI						
Underweight	-11.17 (-44.24-21.91)	0.51	-14.14 (-47.57-19.30)	0.41	-16.46 (-51.07-18.16)	0.35
Normal weight	7.91 (-0.80-16.63)	0.08	-3.79 (-12.17-4.60)	0.38	-4.22 (-12.63-4.20)	0.33
Overweight	13.52 (6.33-20.72)	<0.01	7.81 (0.62-14.99)	0.03	7.33 (0.11-14.57)	<0.05 <sup>a</sup>
Obese	1.65 (-4.64-7.94)	0.61	-1.82 (-7.99-4.34)	0.56	-2.17 (-8.32-3.98)	0.49
Model 1, no variables adjusted; model 2, adjusted for age, sex and race/ethnicity adjusted; model 3, further adjusted for education, ratio of family income to poverty, smoking status, notable alcohol consumption and vigorous activity. <sup>a</sup> P<0.05. PPI, proton pump inhibitor; BMI, body mass index.						

Table SII. Association between PPI use and liver stiffness measurement.						
Characteristic	Model 1		Model 2		Model 3	
	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	P-value
PPI use						
No	0.00		0		0	
Yes	0.27 (-0.08-0.61)	0.13	-0.03 (-0.38-0.32)	0.87	-0.09 (-0.44-0.26)	0.62
PPI						
None	0		0		0	
Omeprazole	0.19 (-0.25-0.63)	0.40	-0.14 (-0.58-0.31)	0.54	-0.19 (-0.63-0.25)	0.40
Pantoprazole	0.31 (-0.34-0.96)	0.36	0.03 (-0.63-0.68)	0.94	-0.05 (-0.70-0.60)	0.88
Esomeprazole	0.48 (-0.60-1.56)	0.38	0.30 (-0.77-1.37)	0.58	0.25 (-0.81-1.32)	0.64
Other	0.65 (-0.81-2.10)	0.3	0.33 (-1.12-1.77)	0.66	0.27 (-1.18-1.71)	0.72
Length of PPI use, years						
Not applicable	0		0		0	
<0.5	-0.05 (-0.98-0.88)	0.92	-0.13 (-1.06-0.79)	0.78	-0.13 (-1.05-0.80)	0.79
0.5-2.0	0.26 (-0.59-1.10)	0.55	0.10 (-0.74-0.94)	0.81	0.02 (-0.82-0.86)	0.96
>2.0	0.33 (-0.07-0.73)	0.11	-0.03 (-0.45-0.38)	0.87	-0.10 (-0.51-0.31)	0.64
Sex						
Male	0.20 (-0.37-0.77)	0.49	-0.14 (-0.72-0.44)	0.64	-0.20 (-0.78-0.39)	0.51
Female	0.40 (-0.01-0.81)	0.05	0.04 (-0.38-0.46)	0.84	-0.03 (-0.45-0.39)	0.88
Age, years						
20-39	-0.40 (-1.51-0.70)	0.48	-0.57 (-1.68-0.53)	0.31	-0.59 (-1.69-0.51)	0.29
40-59	0.31 (-0.27-0.88)	0.30	0.31 (-0.26-0.89)	0.29	0.25 (-0.33-0.83)	0.40
$\geq 60$	-0.13 (-0.66-0.40)	0.63	-0.08 (-0.61-0.45)	0.77	-0.12 (-0.66-0.41)	0.65

Race/ethnicity						
Non-Hispanic White	0.20 (-0.38-0.78)	0.50	0.07 (-0.52-0.67)	0.81	-0.04 (-0.63-0.56)	0.90
Hispanic	0.55 (-0.25-1.34)	0.18	0.04 (-0.77-0.86)	0.92	0.01 (-0.81-0.82)	0.99
Non-Hispanic Black	-0.15 (-0.83-0.54)	0.67	-0.48 (-1.18-0.21)	0.17	-0.54 (-1.24-0.16)	0.13
Non-Hispanic Asian	0.20 (-0.49-0.88)	0.57	0.08 (-0.60-0.75)	0.82	0.05 (-0.63-0.72)	0.89
Other	0.74 (-1.05-2.53)	0.42	0.69 (-1.14-2.53)	0.46	0.84 (-1.03-2.70)	0.38
BMI						
Underweight	-0.03 (-2.03-1.97)	0.98	0.11 (-1.89-2.12)	0.91	0.38 (-1.76-2.52)	0.73
Normal weight	0.39 (-0.06-0.85)	0.09	0.01 (-0.45-0.46)	0.98	0.02 (-0.43-0.48)	0.92
Overweight	0.17 (-0.38-0.71)	0.54	-0.17 (-0.73-0.39)	0.54	-0.24 (-0.80-0.32)	0.40
Obese	-0.16 (-0.78-0.46)	0.62	-0.41 (-1.05-0.22)	0.20	-0.44 (-1.08-0.19)	0.17
Model 1, no variables adjusted; model 2, adjusted for age, sex and race/ethnicity adjusted; model 3, further adjusted for education, ratio of family income to poverty, smoking status, notable alcohol consumption and vigorous activity. PPI, proton pump inhibitor; BMI, body mass index.						

Table SIII. Sensitivity analyses of associations between PPI use and hepatic steatosis (controlled attenuation parameter $\geq 285$ dB/m).						
Characteristic	Model 1		Model 2		Model 3	
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
PPI use						
No	1		1		1	
Yes	1.42 (1.21-1.65)	<0.01	1.21 (1.03-1.42)	0.02	1.19 (1.01-1.40)	0.04 <sup>a</sup>
PPI						
None	1		1		1	
Omeprazole	1.57 (1.29-1.91)	<0.01	1.31 (1.07-1.60)	0.01	1.29 (1.06-1.59)	0.01 <sup>a</sup>
Pantoprazole	1.13 (0.84-1.52)	0.43	1.01 (0.74-1.37)	0.95	0.98 (0.72-1.33)	0.90
Esomeprazole	1.15 (0.71-1.88)	0.57	1.03 (0.62-1.69)	0.92	0.99 (0.60-1.64)	0.98
Other	1.85 (0.97-3.53)	0.06	1.67 (0.86-3.22)	0.13	1.58 (0.82-3.05)	0.17
Length of PPI use, years						
Not applicable	1		1		1	
<0.5	0.95 (0.62-1.47)	0.82	0.88 (0.56-1.36)	0.56	0.89 (0.57-1.38)	0.59
0.5-2.0	1.11 (0.75-1.63)	0.60	1.02 (0.69-1.51)	0.91	1.00 (0.67-1.48)	0.99
>2.0	1.60 (1.34-1.91)	<0.01	1.33 (1.10-1.61)	<0.01	1.30 (1.08-1.57)	<0.01 <sup>a</sup>

Model 1, no variables adjusted; model 2, adjusted for age, sex and race/ethnicity adjusted; model 3, further adjusted for education, ratio of family income to poverty, smoking status, notable alcohol consumption and vigorous activity. <sup>a</sup>P<0.05. PPI, proton pump inhibitor.

Table SIV. Sensitivity analyses of associations between PPI use and hepatic steatosis in patients with non-alcoholic fatty liver disease.						
Characteristic	Model 1		Model 2		Model 3	
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
PPI use						
No	1		1		1	
Yes	1.53 (1.29-1.82)	<0.01	1.29 (1.08-1.55)	<0.01	1.50 (1.16-1.93)	<0.01 <sup>a</sup>
PPI						
None	1		1		1	
Omeprazole	1.60 (1.29-1.98)	<0.01	1.33 (1.06-1.66)	0.01	1.54 (1.13-2.11)	<0.01 <sup>a</sup>
Pantoprazole	1.43 (1.03-1.99)	0.03	1.25 (0.89-1.74)	0.20	1.43 (0.88-2.33)	0.15
Esomeprazole	1.19 (0.67-2.12)	0.55	1.03 (0.57-1.85)	0.92	1.27 (0.57-2.79)	0.56
Other	1.92 (0.92-4.03)	0.08	1.64 (0.77-3.48)	0.20	1.78 (0.63-5.00)	0.28
Length of PPI use, years						
Not applicable	1		1		1	
<0.5	1.18 (0.74-1.88)	0.48	1.06 (0.66-1.70)	0.81	1.45 (0.71-2.97)	0.30
0.5-2.0	1.11 (0.72-1.73)	0.63	0.99 (0.64-1.55)	0.97	1.24 (0.66-2.31)	0.51
>2.0	1.70 (1.39-2.07)	<0.01	1.41 (1.14-1.73)	<0.01	1.55 (1.16-2.08)	<0.01 <sup>a</sup>

Model 1, no variables adjusted; model 2, adjusted for age, sex and race/ethnicity adjusted; model 3, further adjusted for education, ratio of family income to poverty, smoking status, notable alcohol consumption and vigorous activity. <sup>a</sup>P<0.05. PPI, proton pump inhibitor.

Table SV. Sensitivity analysis of associations between PPI use and hepatic steatosis in patients with metabolic dysfunction-associated steatotic liver disease.						
Characteristic	Model 1		Model 2		Model 3	
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
PPI use						
No	1		1		1	
Yes	1.38 (1.16-1.65)	<0.01	1.27 (1.06-1.53)	0.01	1.26 (1.05-1.52)	0.01 <sup>a</sup>
PPI						
None	1		1		1	
Omeprazole	1.45 (1.16-1.81)	<0.01	1.31 (1.05-1.65)	0.02	1.54 (1.13-2.11)	<0.01 <sup>a</sup>
Pantoprazole	1.30 (0.93-1.82)	0.12	1.25 (0.89-1.76)	0.20	1.43 (0.88-2.33)	0.15
Esomeprazole	1.01 (0.57-1.80)	0.97	0.93 (0.52-1.67)	0.81	1.27 (0.57-2.79)	0.56
Other	1.77 (0.83-3.80)	0.14	1.66 (0.77-3.59)	0.20	1.78 (0.63-5.00)	0.28
Length of PPI use, years						
Not applicable	1		1		1	
<0.5	1.22 (0.75-1.98)	0.42	1.17 (0.72-1.91)	0.53	1.19 (0.73-1.95)	0.48
0.5-2.0	0.99 (0.63-1.54)	0.96	0.95 (0.61-1.49)	0.83	0.91 (0.58-1.43)	0.70
>2.0	1.50 (1.23-1.84)	<0.01	1.37 (1.11-1.69)	<0.01	1.36 (1.10-1.68)	<0.01 <sup>a</sup>

Model 1, no variables adjusted; model 2, adjusted for age, sex and race/ethnicity adjusted; model 3, further adjusted for education, ratio of family income to poverty, smoking status, notable alcohol consumption and vigorous activity. <sup>a</sup>P<0.05. PPI, proton pump inhibitor.

Table SVI. Association between H2RA and hepatic steatosis

Characteristic	Model 1		Model 2		Model 3		Model 1		Model 2		Model 3	
	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	OR (95% CI)	P-value	OR (95% CI)	$\beta$ (95% CI)	P-value	OR (95% CI)
H2RA use												
No	0		0		0		1		1		1	
Yes	12.10 (2.97-21.24)	<0.01	6.09 (-2.84-15.02)	0.18	5.75 (-3.15-14.65)	0.21	1.40 (1.04-1.88)	0.03	1.20 (0.89-1.63)	0.24	1.20 (0.88-1.62)	0.25
H2RA												
None	0		0		0		1		1		1	
Ranitidine	18.79 (7.59-29.99)	0.01	12.99 (2.07-23.92)	0.02	12.87 (1.99-23.76)	0.02 <sup>a</sup>	1.77 (1.23-2.55)	<0.01	1.55 (1.06-2.25)	0.02	1.56 (1.07-2.27)	0.02 <sup>a</sup>
Famotidine	0.75 (-15.15-16.66)	0.93	-5.90 (-21.41-9.60)	0.47	-6.65 (-22.12-8.82)	0.40	0.90 (0.53-1.51)	0.69	0.74 (0.44-1.26)	0.27	0.72 (0.42-1.24)	0.23
Length of use, years												
Not applicable	0		0		0		1		1		1	
<0.5	6.67 (-11.74-25.08)	0.48	4.60 (-13.31-22.51)	0.62	4.97 (-12.87-22.82)	0.59	1.31 (0.72-2.37)	0.37	1.25 (0.68-2.29)	0.47	1.28 (0.70-2.36)	0.42
0.5-2.0	15.84 (-6.07-37.75)	0.16	10.38 (-10.94-31.71)	0.34	10.21 (-11.08-31.49)	0.35	1.40 (0.69-2.83)	0.35	1.23 (0.59-2.54)	0.58	1.19 (0.58-2.47)	0.63
>2.0	13.55 (1.64-25.46)	0.03	5.62 (-6.01-17.25)	0.34	4.95 (-6.64-16.55)	0.40	1.47 (1.00-2.15)	0.05	1.19 (0.81-1.77)	0.38	1.18 (0.80-1.76)	0.40
Sex												
Male	11.93 (-2.13-25.98)	0.10	3.45 (-10.35-17.25)	0.62	4.41 (-9.33-18.14)	0.53	1.59 (1.01-2.51)	0.04	1.29 (0.81-2.06)	0.28	1.32 (0.82-2.12)	0.25
Female	13.88 (2.07-25.68)	0.02	8.00 (-3.59-19.58)	0.18	6.72 (-4.84-18.28)	0.26	1.33 (0.90-1.97)	0.16	1.13 (0.76-1.69)	0.54	1.11 (0.74-1.66)	0.62
Age, years												
20-39	5.45 (-23.53-34.44)	0.71	9.29 (-19.02-37.60)	0.52	9.13 (-19.17-37.43)	0.53	0.80 (0.28-2.25)	0.67	0.95 (0.33-2.70)	0.92	0.95 (0.35-2.81)	0.98
40-59	24.64 (8.44-40.85)	<0.01	26.48 (10.46-42.50)	<0.01	26.76 (10.82-42.71)	<0.01 <sup>a</sup>	2.03 (1.16-3.56)	0.01	2.17 (1.23-3.83)	<0.01	2.18 (1.23-3.87)	<0.01 <sup>a</sup>
≥60	-1.55 (-13.05-9.95)	0.79	-3.48 (-14.81-7.84)	0.55	-3.92 (-15.23-7.39)	0.50	1.02 (0.70-1.50)	0.91	0.96 (0.65-1.42)	0.84	0.95 (0.64-1.40)	0.79
Race/ethnicity												
Non-Hispanic												
White	4.95 (-9.40-19.30)	0.50	0.37 (-13.72-14.47)	0.96	1.42 (-12.60-15.44)	0.84	1.09 (0.69-1.73)	0.71	0.94 (0.59-1.51)	0.81	0.97 (0.60-1.55)	0.89
Hispanic	21.60 (2.24-40.96)	0.03	13.29 (-5.78-32.36)	0.17	12.17 (-6.95-31.28)	0.21	1.70 (0.88-3.28)	0.11	1.42 (0.72-2.77)	0.31	1.42 (0.71-2.83)	0.32
Non-Hispanic												
Black	9.16 (-10.24-28.55)	0.36	4.58 (-14.63-23.80)	0.64	5.13 (-14.06-24.32)	0.60	1.61 (0.85-3.05)	0.14	1.43 (0.76-2.72)	0.27	1.46(-0.76-2.79)	0.25
Non-Hispanic												
Asian	12.01 (-15.57-39.58)	0.39	10.97 (-15.78-37.73)	0.42	7.80 (-18.98-34.59)	0.57	1.54 (0.60-3.91)	0.37	1.56 (0.60-4.06)	0.36	1.42 (0.53-3.76)	0.48
Other	21.54 (-17.66-60.73)	0.28	15.09 (-23.62-53.81)	0.45	1.87 (-36.05-39.79)	0.92	1.36 (0.39-4.77)	0.63	1.11 (0.31-4.01)	0.88	0.69 (0.17-2.76)	0.60
BMI												
Normal weight	11.36 (-5.78-28.50)	0.19	1.48 (-14.57-17.52)	0.86	2.04 (-13.99-18.07)	0.80	1.79 (0.72-4.43)	0.21	1.22 (0.48-3.15)	0.68	1.27 (0.49-3.27)	0.62



Overweight	9.54 (-4.57-23.66)	0.19	1.71 (-11.97,-5.38)	0.81	2.16 (-11.60-15.92)	0.76	1.19 (0.70-2.03)	0.53	0.93 (0.53-1.62)	0.80	0.93 (0.53-1.63)	0.81
Obese	1.14 (-10.59-12.88)	0.85	-1.32 (-12.57-9.93)	0.82	-2.21 (-13.43-9.01)	0.70	1.10 (0.70-1.72)	0.68	1.00 (0.63-1.59)	0.99	0.99 (0.62-1.57)	0.96

Model 1, no variables adjusted; model 2, adjusted for age, sex and race/ethnicity adjusted; model 3, further adjusted for education, ratio of family income to poverty, smoking status, notable alcohol consumption and vigorous activity. \*P<0.05. H2RA, H2-receptor antagonists.

Table SVII. Association between H2RA and advanced fibrosis.

Characteristic	Model 1		Model 2		Model 3		Model 1		Model 2		Model 3	
	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	$\beta$ (95% CI)	P-value	$\beta$ (95% CI)	OR (95% CI)	P-value	OR (95% CI)	$\beta$ (95% CI)	P-value	OR (95% CI)
H2RA use												
No	0		0		0		1		1		1	
Yes	1.22 (0.56-1.88)	<0.01	1.02 (0.36-1.68)	<0.01	0.97 (0.31-1.63)	<0.01 <sup>a</sup>	2.37 (1.51-3.71)	<0.01	1.88 (1.19-2.97)	<0.01	1.85 (1.17-2.94)	<0.01 <sup>a</sup>
H2RA												
None	0		0		0		1		1		1	
Ranitidine	1.09 (0.28-1.90)	<0.01	0.87 (0.06-1.67)	0.04	0.83 (0.03-1.64)	0.04 <sup>a</sup>	2.70 (1.60-4.56)	<0.01	2.14 (1.25-3.64)	<0.01	2.14 (1.25-3.66)	<0.01 <sup>a</sup>
Famotidine	1.62 (0.46-2.77)	<0.01	1.46 (0.31-2.60)	0.01	1.38(0.23,2.52)	0.02 <sup>a</sup>	1.85 (0.79-4.34)	0.16	1.47 (0.62-3.49)	0.38	1.39 (0.58-3.30)	0.46
Length of use, years												
Not applicable	0		0		0		1		1		1	
<0.5	1.07 (-0.26-2.41)	0.12	1.04 (-0.28-2.36)	0.12	1.01 (-0.31-2.33)	0.13	1.20 (0.37-3.89)	0.76	1.09 (0.33-3.58)	0.88	1.04 (0.31-3.42)	0.96
0.5-2.0	1.54 (-0.05-3.13)	0.06	1.35 (-0.22-2.93)	0.09	1.34 (-0.24-2.92)	0.10	1.13 (0.27-4.75)	0.87	0.89 (0.21-3.77)	0.87	0.94 (0.22-4.02)	0.93
>2.0	1.21 (0.35-2.07)	<0.01	0.93 (0.07-1.79)	0.03	0.87 (0.01-1.73)	<0.05 <sup>a</sup>	3.35 (2.00-5.62)	<0.01	2.53 (1.49-4.28)	<0.01	2.48 (1.46-4.21)	<0.01 <sup>a</sup>
Sex												
Male	1.33 (0.23-2.44)	0.02	1.00 (-0.11-2.12)	0.08	0.96 (-0.16-2.07)	0.09	2.59 (1.41-4.75)	<0.01	1.90 (1.02-3.53)	0.04	1.95 (1.04-3.64)	0.04 <sup>a</sup>
Female	1.22 (0.45-1.99)	<0.01	1.02 (0.25-1.79)	0.01	0.96 (0.19-1.73)	0.02 <sup>a</sup>	2.31 (1.18-4.51)	0.02	1.88 (0.95-3.72)	0.07	1.79 (0.90-3.57)	0.10
Age, years												
20-39	4.08 (2.28-5.89)	<0.01	4.11 (2.32-5.91)	<0.01	4.17 (2.38-5.96)	<0.01 <sup>a</sup>	4.19 (0.94-18.59)	0.06	4.34 (0.95-19.77)	0.06	3.93 (0.83-18.58)	0.08
40-59	1.39 (0.35-2.43)	<0.01	1.45 (0.41- 2.48)	<0.01	1.42 (0.39-2.46)	<0.01 <sup>a</sup>	3.54 (1.70-7.40)	<0.01	3.69 (1.75-7.76)	<0.01	3.65 (1.71-7.79)	<0.01 <sup>a</sup>
$\geq 60$	0.28 (-0.75-1.31)	0.59	0.32 (-0.71- 1.35)	0.54	0.25 (-0.78-1.28)	0.63	1.29 (0.70-2.38)	0.42	1.29 (0.69-2.39)	0.43	1.27 (0.68-2.37)	0.45
Race/ethnicity												
Non-Hispanic White	2.13 (0.96-3.30)	<0.01	2.04 (0.87-3.21)	<0.01	2.05 (0.87-3.22)	<0.01 <sup>a</sup>	2.13 (1.07-4.22)	0.03	1.82 (0.91-3.65)	0.09	1.91 (0.95-3.86)	0.07
Hispanic	1.14 (-0.29-2.57)	0.12	0.65 (-0.78-2.07)	0.37	0.55 (-0.88-1.99)	0.45	4.03 (1.81-8.98)	<0.01	2.64 (1.16-6.05)	0.02	2.63 (1.12-6.15)	0.03 <sup>a</sup>
Non-Hispanic Black	0.08 (-1.28-1.44)	0.90	-0.08 (-1.43-1.28)	0.91	-0.18 (-1.54-1.17)	0.79	2.05 (0.71-5.87)	0.18	1.78 (0.61-5.16)	0.29	1.60 (0.55-4.71)	0.39
Non-Hispanic Asian	-0.21 (-1.31-0.90)	0.72	-0.21 (-1.29-0.88)	0.71	-0.30 (-1.39-0.78)	0.59						
Other	1.34 (-1.72-4.39)	0.39	1.20 (-1.84-4.24)	0.44	0.72 (-2.34-3.79)	0.64	1.69 (0.20-13.92)	0.63	1.56 (0.18-13.15)	0.68	1.50 (0.16-14.55)	0.73
BMI												
Normal weight	0.07 (-0.82-0.96)	0.88	-0.19 (-1.06-0.69)	0.68	-0.21(-1.08,0.66)	0.63	3.49 (0.80-15.23)	0.10	2.06 (0.45-9.49)	0.35	2.04 (0.42-9.90)	0.37
Overweight	2.04 (0.97-3.10)	<0.01	1.74 (0.68-2.80)	<0.01	1.71(0.64,2.77)	0.02 <sup>a</sup>	3.04 (1.18-7.83)	0.02	1.86 (0.70-4.96)	0.21	1.82 (0.67-4.91)	0.24

Obese	0.85 (-0.30-2.01)	0.15	0.71 (-0.45-1.87)	0.23	0.70(-0.46,1.86)	0.24	1.86 (1.07-3.23)	0.03	1.60 (0.91-2.80)	0.10	1.60 (0.91-2.83)	0.10
Model 1, no variables adjusted; model 2, adjusted for age, sex and race/ethnicity adjusted; model 3, further adjusted for education, ratio of family income to poverty, smoking status, notable alcohol consumption and vigorous activity. <sup>a</sup> P<0.05. H2RA, H2-receptor antagonist.												